Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Titan Medical Inc.
  6. News
  7. Summary
    TMD   CA88830X8199

TITAN MEDICAL INC.

(TMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

TITAN MEDICAL ANNOUNCES COMPLETION OF PRE-CLINICAL GLP STUDIES

10/26/2021 | 05:09am EST

TORONTO - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced that it has completed its scheduled pre-clinical studies with its Enos robotic single access surgical system, performed in accordance with FDA's good laboratory practice (GLP) regulations. GLP is a set of principles intended to assure the quality and integrity of non-clinical laboratory studies that are intended to support marketing permits for products regulated by government agencies.

Titan's pre-clinical studies involved utilizing the Enos system to perform hysterectomies in porcine subjects. Initial testing has been successfully completed and in accordance with GLP principles, further tests on the subjects were run post-surgery and pathology results are expected over the next several months. The COVID-19 pandemic has impacted the processing time at laboratories, resulting in a longer than expected turnaround time for results. With the completion of these studies, surgeons have now performed over 70 pre-clinical procedures representing multiple subspecialties with Titan's Enos system.

'We are pleased to report that the studies were completed on time, adding to the cadre of data supporting the Enos system's use in pre-clinical studies. These studies provide critical input toward the final steps of development in preparation for regulatory submissions. We look forward to finalizing product development of the Enos system and continuing with our plans for application for investigational device exemption with the FDA, and once approved, proceeding with clinical studies,' stated David McNally, President and Chief Executive Officer of Titan.

About Titan Medical Inc.

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company headquartered in Toronto, Ontario and with R&D facilities in Chapel Hill, North Carolina, is focused on enhancing robotic assisted surgery using innovative technology through a single access point. The Enos robotic single access surgical system is being developed with an ergonomic focus to provide a surgical experience that imitates real-life movements that surgeons demand, and includes multi-articulating instruments designed to allow surgeons an increased range of motion in a confined space, with dexterity and the ability to exert the forces necessary to complete common surgical tasks. With the Enos system, Titan intends to initially pursue gynecologic surgical indications. Certain of Titan's robotic assisted surgical technologies and related intellectual property have been licensed to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system.

Enos is a trademark of Titan Medical Inc.

For more information, visit www.titanmedicalinc.com.

Forward-Looking Statements

This news release contains 'forward-looking statements' within the meaning of applicable Canadian and U.S. securities laws. Such statements reflect the current expectations of management of the company's future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as 'may', 'would', 'could', 'will', 'anticipate', 'believe', 'plan', 'expect', 'intend', 'estimate', 'potential for' and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to: the company's focus on the design and development of surgical technologies for robotic single access surgery; the company's expectation for receiving post-surgery testing results from the pre-clinical studies over the next several months; the company's estimation of completing product development of the Enos system; the company's plans with respect to regulatory submissions, including for an investigational device exemption, with the FDA; the company's plans for clinical studies; the company's intention to initially pursue gynecologic surgical indications with the Enos system; and the license of certain of Titan's robotic assisted surgical technologies and related intellectual property to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the 'Risk Factors' section of the company's Annual Information Form and Form 40-F for the fiscal year ended December 31, 2020 (which may be viewed at www.sedar.com and at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Contact:

Kristen Galfetti

Vice President

Investor Relations & Corporate Communications

T: +1-781-869-2553

E: investors@titanmedicalinc.com

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
MEDTRONIC PLC -0.69% 110.28 Delayed Quote.-5.86%
TITAN MEDICAL INC. -3.23% 0.9 Delayed Quote.-57.14%
All news about TITAN MEDICAL INC.
11/12Expanded Surgeon Advisory Board Completed GLP Studies Enos System Commercial Launch Tim..
PU
11/11Titan Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended..
CI
11/11Titan Medical Reports Third Quarter 2021 Financial Results
BU
11/03Titan Medical Announces Expansion of Surgeon Advisory Board - Form 6-K
PU
11/03Titan Medical Announces Expansion of Surgeon Advisory Board
BU
11/03Titan Medical Announces Expansion of Surgeon Advisory Board
CI
11/01Titan Medical to Report Third Quarter 2021 Financial Results on November 11, 2021 - For..
PU
11/01Titan Medical to Report Third Quarter 2021 Financial Results on November 11, 2021
BU
10/26Titan medical announces completion of pre-clinical glp studies
AQ
10/25TITAN MEDICAL : up 1.8% in US Pre-Market as Announces Completion of Pre-Clinical GLP Studi..
MT
More news
Analyst Recommendations on TITAN MEDICAL INC.
More recommendations
Financials
Sales 2021 26,5 M 20,8 M 20,8 M
Net income 2021 -34,4 M -27,0 M -27,0 M
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 103 M 80,8 M 81,1 M
Capi. / Sales 2021 3,90x
Capi. / Sales 2022 -
Nbr of Employees 9
Free-Float 99,7%
Chart TITAN MEDICAL INC.
Duration : Period :
Titan Medical Inc. Technical Analysis Chart | TMD | CA88830X8199 | MarketScreener
Technical analysis trends TITAN MEDICAL INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
David J. McNally President, Chief Executive Officer & Director
Stephen L. Lemieux Chief Financial Officer
Paul G. Cataford Chairman
Perry A. Genova Senior Vice President-Research & Development
Anthony J. Giovinazzo Independent Director
Sector and Competitors